Indian Oncologists Are Starting to Embrace Use of Targeted Agents Despite Their High Cost, According to a Report from Decision Resources
WALTHAM, Mass., April 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Sanofi-Aventis' Eloxatin, Indian brand/generics (oxaliplatin) and Roche/Chugai's Xeloda, Indian brand/generics (capecitabine) will dominate the Indian colorectal cancer drug market through 2013. However, as a result of the increased use of targeted agents and rapid growth of the Indian colorectal cancer drug market the combined market share of these two drugs will fall from 67 percent in 2008 to 52 percent in 2013.
The new Emerging Markets report entitled Colorectal Cancer in India also finds that Indian oncologists are starting to embrace use of targeted agents such as Roche/Chugai's Avastin (bevacizumab) and Merck KGaA/Bristol-Myers Squibb's Erbitux (cetuximab) despite their high cost. Growth of these agents and the launch of Amgen's Vectibix (panitumumab) will ensure that sales of targeted agents rise from $3.1 million in 2008 to $13.5 million in 2013.
"The increased use of targeted agents like Avastin and Erbitux is due to the increasing wealth and urbanization among India's population and because their efficacy and toxicity are superior to those of conventional therapies," stated Marcus Hoyle, analyst at Decision Resources.
About Emerging Markets Reports
Emerging Markets is a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 email@example.com firstname.lastname@example.org
|SOURCE Decision Resources|
Copyright©2009 PR Newswire.
All rights reserved